Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03205683
Recruitment Status : Completed
First Posted : July 2, 2017
Last Update Posted : September 10, 2019
Sponsor:
Information provided by (Responsible Party):
Bryan Tsao, Loma Linda University

Brief Summary:
We hypothesize that a standard course of INF can result in significant improvement in CTS as measured by clinical, electrodiagnostic, or ultrasound measures.

Condition or disease Intervention/treatment Phase
Carpal Tunnel Syndrome Other: Intraneural facilitation (INF) Other: Sham INF Not Applicable

Detailed Description:
INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve. his therapy has been shown to improve clinical function in patients with diabetic-associated polyneuropathy, a model for various forms of ischemic neuropathy. CTS is a common condition where regional compression at the wrist results in ischemic focal demyelination of the distal median nerve. This results in sensory dysfunction, pain, and eventually axon loss and weakness if the compression is sufficiently severe and prolonged. Standard therapy for CTS includes wrist splints, regional lidocaine injections, ergonomic adjustments, various forms of occupation therapy, and ultimately surgical release of the carpal tunnel ligament. However, all of these are either temporary in their effect or invasive. The diagnosis of CTS relies on clinical, electrodiagnostic or NCS, and ultrasound methods.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome
Actual Study Start Date : January 29, 2018
Actual Primary Completion Date : February 22, 2019
Actual Study Completion Date : February 22, 2019


Arm Intervention/treatment
Experimental: Intraneural facilitation therapy
The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
Other: Intraneural facilitation (INF)
INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.

Sham Comparator: Sham therapy

Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).

Missing > 4 sessions will invalidate subject outcomes.

Other: Sham INF
Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.




Primary Outcome Measures :
  1. The Boston CTS Questionnaire symptom severity scale and functional assessment. [ Time Frame: change between baseline and one week after completion of INF therapy ]
    composite measurement of carpal tunnel symptomology (pain and numbness) and functional assessment

  2. The Boston CTS Questionnaire symptom severity scale and functional assessment. [ Time Frame: change between week 1 and 3 months after completion of INF therapy ]
    composite measurement of carpal tunnel symptomology (pain and numbness) and functional assessment


Secondary Outcome Measures :
  1. Visual analog scale (VAS) [ Time Frame: change between baseline and one week after completion of INF therapy ]
    an ordinal standardized scale grading pain from 0 (absent) to 10 (greatest)

  2. Visual analog scale (VAS) [ Time Frame: change between week 1 and 3 months after completion of INF therapy ]
    an ordinal standardized scale grading pain from 0 (absent) to 10 (greatest)

  3. Ultrasound [ Time Frame: change between baseline and one week after completion of INF therapy ]
    Reduction in diameter of the median nerve at the wrist or in the distal forearm ratio



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Patients referred to the LLUH Neurology Electrodiagnostic Laboratory with electrodiagnostic and clinical evidence of CTS (uni- or bilateral)
  2. Ages >18 and < 75 (irrespective of gender)
  3. Current use of splints as long as the frequency of treatment is unaltered and onset of use is > 1 week in duration

Exclusion Criteria:

  1. Prior carpal tunnel release > 2 years ago
  2. The presence of any condition that would prevent NCS from accurately diagnosing CTS (e.g., hereditary polyneuropathy or acquired demyelinating polyneuropathy)
  3. Workman's Compensation cases
  4. Pregnancy
  5. Undergoing conservative or surgical/injection therapy (physical or occupational therapy, injections)
  6. Clinically silent CTS in face of positive electrodiagnostic results
  7. Sufficiently severe clinical symptoms that warrant more aggressive therapy i.e., carpal injections or release
  8. Any confounding medical condition that the investigator deems may adversely affect subject participation or outcomes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03205683


Locations
Layout table for location information
United States, California
Loma Linda University Health
Loma Linda, California, United States, 92354
Sponsors and Collaborators
Loma Linda University
Investigators
Layout table for investigator information
Principal Investigator: Bryan Tsao, MD Loma Linda University
Layout table for additonal information
Responsible Party: Bryan Tsao, Neurology Chairman, Loma Linda University
ClinicalTrials.gov Identifier: NCT03205683    
Other Study ID Numbers: 5170247
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: September 10, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carpal Tunnel Syndrome
Syndrome
Disease
Pathologic Processes
Median Neuropathy
Mononeuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Nerve Compression Syndromes
Cumulative Trauma Disorders
Sprains and Strains
Wounds and Injuries